title: Effects of growth hormone treatment in adults with Prader-Willi syndrome.
abstract: OBJECTIVE
  Since limited data exist on adults with Prader-Willi syndrome (PWS) and growth hormone (GH) treatment, we report our experience on the effects of treatment for one year on body composition, physical activity, strength and energy expenditure, diet, general chemistry and endocrine data with quality of life measures.
  
  
  METHODS
  We studied 11 adults with PWS (6F:5M; average age=32 yrs) over a 2 year period with GH treatment during the first year only. Electrolytes, IGF-I, glucose, thyroid, insulin, lipids, body composition, physical activity and strength, diet, energy expenditure and quality of life data were collected and analyzed statistically using linear modeling at baseline, at 12 months following GH therapy and at 24 months after treatment cessation for 12 months.
  
  
  RESULTS
  Total lean muscle mass was significantly increased (p<0.05) during GH treatment along with moderate-vigorous physical activity and plasma IGF-I and HDL levels, but returned to near baseline after treatment. Percent body fat decreased during the 12 months of GH treatment but increased after treatment.
  
  
  CONCLUSIONS
  Previously reported beneficial effects of GH treatment in children with PWS were found in our adults regarding body composition, physical activity and plasma HDL and IGF-I levels. Several beneficial effects diminished to near baseline after cessation of GH treatment for 12 months supporting the continuation of treatment in PWS into adulthood and possibly adults not previously treated during childhood.
authors: Department of Psychiatry & Behavioral Sciences, University of Kansas Medical Center, and Department of Pediatrics, Children's Mercy Hospital, Kansas City, United States. mbutler4@kumc.edu
authors: M G
authors: MG
authors: Butler
authors: B K
authors: BK
authors: Smith
authors: J
authors: J
authors: Lee
authors: C
authors: C
authors: Gibson
authors: C
authors: C
authors: Schmoll
authors: W V
authors: WV
authors: Moore
authors: J E
authors: JE
authors: Donnelly
mesh_terms: D000273:Adipose Tissue; D000293:Adolescent; D000328:Adult; D001823:Body Composition; D004734:Energy Metabolism; D015444:Exercise; D005215:Fasting; D019382:Human Growth Hormone / Q000008:administration & dosage*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D008055:Lipids / Q000032:analysis; D008297:Male; D008875:Middle Aged; D011218:Prader-Willi Syndrome / Q000097:blood / Q000188:drug therapy*; D011379:Prognosis; D011788:Quality of Life; D055815:Young Adult
chemical_list: D008055:Lipids; D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I